Keywords: fda, calls, stronger, warnings, esas, aranesp, epogen
US FDA calls for stronger warnings on ESAs Aranesp, Epogen and Procrit
Article | 19 November 2007
Following concerns earlier this year about the safety of erythropoiesis-stimulating agents (Marketletters February 26 and March 19), the US Food and Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
